Biblio

Export 751 results:
Author Title Type Year
Filters: First Letter Of Keyword is P  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Peptide Fragments
A. Koppara, Wolfsgruber, S., Kleineidam, L., Schmidtke, K., Frölich, L., Kurz, A., Schulz, S., Hampel, H., Heuser, I., Peters, O., Reischies, F. M., Jahn, H., Luckhaus, C., Hüll, M., Gertz, H. - J., Schröder, J., Pantel, J., Rienhoff, O., Rüther, E., Henn, F., Wiltfang, J., Maier, W., Jessen, F., Kornhuber, J., and Wagner, M., The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment., J Alzheimers Dis, vol. 49, no. 2, pp. 547-60, 2016.
P. Banerjee, Sahoo, A., Anand, S., Bir, A., and Chakrabarti, S., The Oral Iron Chelator, Deferasirox, Reverses the Age-Dependent Alterations in Iron and Amyloid-β Homeostasis in Rat Brain: Implications in the Therapy of Alzheimer's Disease., J Alzheimers Dis, vol. 49, no. 3, pp. 681-93, 2016.
J. C. Morris, Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., and Mintun, M. A., APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging., Ann Neurol, vol. 67, no. 1, pp. 122-31, 2010.
G. He, Luo, W., Li, P., Remmers, C., Netzer, W. J., Hendrick, J., Bettayeb, K., Flajolet, M., Gorelick, F., Wennogle, L. P., and Greengard, P., Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease., Nature, vol. 467, no. 7311, pp. 95-8, 2010.
A. Ezra, Rabinovich-Nikitin, I., Rabinovich-Toidman, P., and Solomon, B., Multifunctional Effect of Human Serum Albumin Reduces Alzheimer's Disease Related Pathologies in the 3xTg Mouse Model., J Alzheimers Dis, vol. 50, no. 1, pp. 175-88, 2016.
J. Gräff, Rei, D., Guan, J. - S., Wang, W. - Y., Seo, J., Hennig, K. M., Nieland, T. J. F., Fass, D. M., Kao, P. F., Kahn, M., Su, S. C., Samiei, A., Joseph, N., Haggarty, S. J., Delalle, I., and Tsai, L. - H., An epigenetic blockade of cognitive functions in the neurodegenerating brain., Nature, vol. 483, no. 7388, pp. 222-6, 2012.
D. Head, Bugg, J. M., Goate, A. M., Fagan, A. M., Mintun, M. A., Benzinger, T., Holtzman, D. M., and Morris, J. C., Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition., Arch Neurol, vol. 69, no. 5, pp. 636-43, 2012.
P. Buchhave, Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., and Hansson, O., Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia., Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
M. Babić Leko, Borovečki, F., Dejanović, N., Hof, P. R., and Šimić, G., Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment., J Alzheimers Dis, vol. 50, no. 3, pp. 765-78, 2016.
K. Bourgade, Le Page, A., Bocti, C., Witkowski, J. M., Dupuis, G., Frost, E. H., and Fülöp, T., Protective Effect of Amyloid-β Peptides Against Herpes Simplex Virus-1 Infection in a Neuronal Cell Culture Model., J Alzheimers Dis, vol. 50, no. 4, pp. 1227-41, 2016.
F. Piazza, Greenberg, S. M., Savoiardo, M., Gardinetti, M., Chiapparini, L., Raicher, I., Nitrini, R., Sakaguchi, H., Brioschi, M., Billo, G., Colombo, A., Lanzani, F., Piscosquito, G., Carriero, M. Rita, Giaccone, G., Tagliavini, F., Ferrarese, C., and DiFrancesco, J. C., Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies., Ann Neurol, vol. 73, no. 4, pp. 449-58, 2013.
O. Bousiges, Cretin, B., Lavaux, T., Philippi, N., Jung, B., Hezard, S., Heitz, C., Demuynck, C., Gabel, A., Martin-Hunyadi, C., and Blanc, F., Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies., J Alzheimers Dis, vol. 51, no. 4, pp. 1069-83, 2016.
H. Li, Zhu, H., Wallack, M., Mwamburi, M., Abdul-Hay, S. O., Leissring, M. A., and Qiu, W. Qiao, Age and its association with low insulin and high amyloid-β peptides in blood., J Alzheimers Dis, vol. 49, no. 1, pp. 129-37, 2016.
G. Berge, Lauridsen, C., Sando, S. Botne, Holder, D. Joseph, Møller, I., Aasly, J. Olav, Bråthen, G., Savage, M. Josephine, and White, L. Rosemary, Effect of Tween-20 on Core Biomarkers Measured in Cerebrospinal Fluid from Patients with Alzheimer's Disease, Mild Cognitive Impairment, or Healthy Control Individuals., J Alzheimers Dis, vol. 49, no. 2, pp. 493-502, 2016.
T. Minh Do, Dodacki, A., Alata, W., Calon, F., Nicolic, S., Scherrmann, J. - M., Farinotti, R., and Bourasset, F., Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD)., J Alzheimers Dis, vol. 49, no. 2, pp. 287-300, 2016.
E. C. Pinnock, Jovanovic, K., Pinto, M. G., Ferreira, E., Dias, B. Da Costa, Penny, C., Knackmuss, S., Reusch, U., Little, M., Schatzl, H. M., and Weiss, S. F. T., LRP/LR Antibody Mediated Rescuing of Amyloid-β-Induced Cytotoxicity is Dependent on PrPc in Alzheimer's Disease., J Alzheimers Dis, vol. 49, no. 3, pp. 645-57, 2016.
L. García Barrado, Coart, E., Vanderstichele, H. M. J., and Burzykowski, T., Transferring cut-off values between assays for cerebrospinal fluid Alzheimer's disease biomarkers., J Alzheimers Dis, vol. 49, no. 1, pp. 187-99, 2016.
M. Bjerke, Kern, S., Blennow, K., Zetterberg, H., Waern, M., Börjesson-Hanson, A., Östling, S., Kern, J., and Skoog, I., Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years., J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.

Pages